Evaluation of the Renal Function in an Ultra-endurance Race.

Renal Function Evaluation in an Ultra Endurance Race: On the Interest of Monitoring Specific Biomarkers to Asses Renal Risk.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03136315

Acronym

INFERNAL

Enrollment

Registered

2017-05-02

Start date

2017-09-07

Completion date

2017-09-10

Last updated

2017-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Insufficiency, Acute

Keywords

Renal failure, athlete, ultra endurance

Brief summary

During ultra endurance events, athletes experience extreme physical and mental demands, sometimes at the limits of the adaptive response to human physiology. This is particularly true for the renal function, and some evidence for acute renal failure has already been shown, sometimes leading to dialysis. However, the precise mechanisms involved in acute renal failure in such ultra endurance races are not clearly elucidated. The aim of our study is to estimate glomerular filtration rate from serum and urinary creatinine and cystitin C at the beginning and at the end of a 110 km ultra endurance race. Our hypothesis is that during the ultra endurance race, renal function may be injured, with a risk for the athlete.

Interventions

OTHERINFERNAL Intervention

The intervention consists in serum and urinary dosage (creatinine and Cystatin C) at the beginning and the end of the 110 km race.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Age: At least 20 years old * Athlete that is officially registered to the 110 km race (INFERNAL Trail des Vosges) * Athlete informed by a member (MD) of the Medical Staff of the race. * Athlete that gives and signes the informed consent to the research protocol

Exclusion criteria

* Athlete with a known disease that needs the following medications: * Medications influencing the renin-angiotensin-aldosteron system (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, aldosteron receptor blockers) * Diuretic drugs * Anticoagulant drugs * Non-steroidal anti-inflammatory drugs * Athlete with a known thyroid disease (because of the influence on the serum cystatin level) * Athlete with a know renal disease * Athlete with a know inflammatory disease

Design outcomes

Primary

Measure	Time frame	Description
Glomerular filtration rate	30 minutes at baseline (09.07.2017), and 30 minutes at the end of the 110 km race (2 or 3 days after baseline)	The glomerular filtration rate will be calculated from the serum and urinary creatinine and cystatin C dosage

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026